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Since 1998, oral hydration 
and oral antibiotics have been 
proposed in pat ients  with 
uncomplicated diverticulitis (UD) 
[1]. However, recommendations 
for outpatient management of UD 
were vague [2]. In addition, the 
evidence supporting outpatients 
with UD with oral antibiotics was 
limited and an important number 
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ABSTRACT
In this session diverse critical issues in diverticular disease (DD) were considered, including “In or outpatient 
management of uncomplicated diverticulitis?”, “Segmental colitis associated with diverticulosis: what is it?”and 
“Diverticular inflammation is a risk factor for colorectal cancer?”. The conclusions drawn are outlined in the 
statements but in summary, outpatient management is safe in selected patients, as long as correct diagnosis 
and stage are assured, and this can allow a cost effective treatment. Non-antibiotic management is also safe 
but should be confined as an outpatient treatment in carefully selected patients.  
Segmental colitis associated with diverticulosis (SCAD) is a defined pathological entity (only diagnosed on 
biopsy) characterized by an inflammatory bowel disease (IBD)-like pathology, occurring principally in the 
sigmoid colon, with rectal and right colon sparing.  The pathogenesis is unclear but may include a genetic 
predisposition, microbiome alteration and ischaemia. Treatment can last months, and depends on severity, 
options include antibiotics, 5-ASA and probiotics for mild cases. Severe disease needs systemic steroids or 
even anti TNFα treatment.  
Whether diverticular inflammation is a risk factor for colorectal cancer (CRC) was debated and the conclusion 
was that within the first eighteen months of diagnosis of DD, associations with cancer are found, likely due 
to similar symptoms and misclassification of disease. After that time, DD does not increase the risk of CRC. 
Therefore, it is recommended to exclude cancer with imaging and colonoscopy after healing of the first 
episode of diverticulitis.
Key words: colonoscopy – colorectal cancer – diverticular disease – segmental colitis associated with 
diverticulosis.    
Abbreviations: CRC: colorectal cancer; DD: diverticular disease; DICA: Diverticula Inflammation and 
Complications Assessment; CT: computer tomography; SCAD: segmental colitis associated with diverticulosis; 
UD: uncomplicated diverticulitis. 
of patients was still admitted to the hospital for DD without 
abscess or perforation [3].  
In a Spanish study from 2010 including  96 patients with UD, 
ambulatory treatment was initiated in 70 (73%) patients. Only 
two (3%) required admission because of persisting abdominal 
pain and vomiting. In the remaining 68 (97%), ambulatory 
treatment was completed without any complication (4).  
Two recent studies, one randomized trial and one 
systematic review confirm that ambulatory treatment of UD 
is safe, effective, and economically efficient when applying an 
appropriate selection of patients [5, 6[. Intolerance to oral intake 
and lack of family or social support are common exclusion 
criteria used for this approach, while severe comorbidities are 
not definitive exclusion criteria in all the studies.  
Since non-antibiotic management of acute UD has been 
shown to be safe, the new controversy is on the efficacy 
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and safety of outpatient treatment of UD associated with 
non-antibiotic policy. In a recent prospective observational 
study, 155 patients with UD were managed as outpatients 
without antibiotics and most of them (97.4%) were managed 
successfully [7].  
The decision for outpatient treatment without antibiotics 
should be based on the knowledge of risk factors potentially 
related with failure of non-antibiotics policy or with 
complications occurred in initially UD. It seems that high CRP 
level, systemic comorbidity, symptoms for more than five days 
and the presence of vomit are significant predictive factors for 
treatment failure [8, 9]. 
In conclusion, outpatient management of UD in selected 
patients is safe and effective allowing important cost saving. The 
possibility of an outpatient treatment of UD is conditioned by 
an accurate diagnosis and staging. Non-antibiotic management 
is safe, and it could be associated with outpatient management 
only in selected patients.  
SEGMENTAL COLITIS ASSOCIATED 
WITH DIVERTICULOSIS (SCAD): WHAT 
IS IT? 
SCAD is a defined pathological entity characterized by an 
inflammatory process of the inter-diverticular mucosa of the 
colonic segment involved. The rectum and the right colon are 
spared from inflammation [10]. Limitation of mucosal lesions 
to the diverticular segment is the most important diagnostic 
criterion for SCAD (rectal sparing). Rectal and descending 
colon biopsies are required to distinguish SCAD from IBD [10]. 
The disease is relatively rare, with a prevalence of 0.25-
1.4% in the general population and 1.15-11.4% amongst DD 
patients. Mean age at diagnosis is early to mid 60s, with a 
slightly higher male preponderance [11-13]. The pathogenesis 
is multifactorial, and includes genetic susceptibility, alteration 
in bowel microbiome, local ischaemia, mucosal prolapse and 
more [11, 14].  
The clinical presentation as well as the endoscopic and 
histological appearance vary in the four major subtypes. Type 
A is characterized endoscopically by red patches involving 
colonic folds and diverticular sparing with neutrophil and 
lymphocyte infiltrates limited to crypt epithelium. Type B and 
D are characterized by ulcerative colitis (UC)- like changes 
endoscopically and histologically, with erosions and hyperemic 
areas involving the colonic folds and severe inflammation 
involving the overall diverticula containing mucosa, 
respectively. Histological changes in both subtypes involve 
crypt distortion and crypt abscesses. Type C is characterized 
by Crohn’s disease like changes, with isolated aphthous ulcers 
and transmural inflammatory changes [15, 16].  
Treatment options include antibiotics (ciprofloxacin and 
metronidazole), 5-ASA and probiotics for mild cases. In severe 
disease, use of systemic steroids might be warranted. Anti 
TNFα treatment may be beneficial in sever disease resistant 
to other therapeutic options. Treatment duration might vary 
depending on clinical response and can last weeks to months 
[15-17]. 
IS DIVERTICULAR INFLAMMATION 
A RISK FACTOR FOR COLORECTAL 
CANCER?
Older studies searching associations between DD and CRC 
have described a clear overall association suggesting that long-
term inflammation can lead to cancer. However, only recently 
this association has been questioned. Authors of three large 
studies analysed separately periods within vs. outside 1.5 years 
from the diagnosis of DD or diverticulitis. 
In the first study Granlund et al. [18] performed a 
nationwide, case-control study. They identified 41,037 patients 
with CRC based on Cancer Register and age and gender 
matched controls  without cancer, with a proportion of 1 to 2. 
Then they searched in the Swedish Inpatient Register preceding 
hospitalizations with the diagnosis of DD. Authors clearly have 
shown that the association between CRC and DD was present 
only when DD was diagnosed up to 18 months before CRC.  
Using different methodology Huang et al. [19] in Taiwan 
first identified 45,662 inpatients with DD, that were matched 
by age, sex, year of hospitalisation with 182,488 controls 
without DD. CRC diagnosis was then searched in following 
hospitalisations in both groups. Again, authors have shown 
that after excluding the 1st year of observation CRC incidence 
was similar in both groups for remaining years of follow-up.   
Lastly, Mortensen et al. [20] in Denmark using similar 
methodology to Huang et al. (40,496 patients with  DD and 
404,960 matched controls) showed that overwhelming majority 
of CRC diagnosis were within +/- 500 days from the first 
diagnosis of diverticulitis. 
In conclusion, within the first 1.5 year of diagnosis 
of DD associations with cancer is strong probably due 
to similar symptoms and misclassifications. After that 
period, DD does not increase the risk of CC. Therefore, it is 
recommended to exclude CRC using modern technologies 
(including colonoscopy) after healing of the first episode of 
diverticulitis. 
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